Latest News - Imprimis Pharmaceuticals

Monday, August 15, 2016 | Management/Leadership, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Expands its Leadership Team in Operations, Quality, Manufacturing, and Client Relations

Imprimis Pharmaceuticals reported the expansion of its leadership team with the appointments of Clayton Edwards as Senior Vice President of Operations; Eric Rice as Vice President of Client Relations;…

Read the full story

Friday, July 29, 2016 | Product Releases, Imprimis Pharmaceuticals

Imprimis Launches New MaxRx Prescriber Portal

Imprimis Pharmaceuticals announced the availability of its new MaxRx Prescriber Portal, a software application that provides physicians with new order entry and management tools that have traditionall…

Read the full story

Friday, July 22, 2016 | Cataract Surgery, Medical Studies, Imprimis Pharmaceuticals

Peer-Reviewed Study of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared to Drops

Imprimis Pharmaceuticals announced that positive results of a clinical study comparing the efficacy of its injected triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin (Tri-Moxi-Vanc) …

Read the full story

Thursday, May 12, 2016 | Clinical Trials, Imprimis Pharmaceuticals

Imprimis’ Tri-Moxi-Vanc Dropless Therapy Formulation Shows Statistically Significant Reduction in Cystoid Macular Edema in Patients Following Cataract Surgery

Imprimis Pharmaceuticals announced the positive results of an investigator-initiated clinical study of the company’s triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin (Tri-Moxi…

Read the full story

Thursday, May 05, 2016 | Product Releases, Imprimis Pharmaceuticals

Imprimis Launches IV Free Conscious Sedation and New Compounded Triple Drop Formulations

Imprimis Pharmaceuticals announced plans to launch its IV Free MKO Melt conscious sedation formulations and new triple combination eye drop, which includes nepafenac, at the ASCRS meeting in New …

Read the full story

Thursday, December 17, 2015 | Partnerships, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Announces National Account Agreement with the Cataract & Laser Institute

Imprimis Pharmaceuticals and Cataract & Laser Institute announced that they have entered into a national account agreement to provide Imprimis' Dropless Cataract Therapy to patients at the…

Read the full story

Tuesday, November 24, 2015 | Partnerships, Imprimis Pharmaceuticals

Nvision Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

Imprimis Pharmaceuticals and Nvision Eye Centers, one of the largest US providers of LASIK and cataract surgery, announced they have entered into an agreement to provide Nvision Eye Center patients wi…

Read the full story

Thursday, November 12, 2015 | Conferences, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals' Ophthalmic Formulations to be Presented at AAO

Imprimis Pharmaceuticals announced its ophthalmic formulations and outcomes from a recent economic study will be featured in presentations, courses, and related events at the annual American Aca…

Read the full story

Monday, October 26, 2015 | Medical Studies, Imprimis Pharmaceuticals

Study: Wider Adoption of Dropless Therapy Would Save Medicare Billions

A study from the nonprofit group Cataract Surgeons for Improved Eyecare (CSIE) reports that wider adoption of “dropless” therapy in connection with cataract surgeries could save Medi…

Read the full story

Friday, October 23, 2015 | Miscellaneous, Imprimis Pharmaceuticals

Imprimis to Make Compounded and Customizable Formulation of Pyrimethamine and Leucovorin Available as an Alternative to Daraprim

Imprimis Pharmaceuticals announced it has made available a customizable compounded formulation of pyrimethamine and leucovorin available for physicians to consider prescribing for their patients as a …

Read the full story

Wednesday, August 12, 2015 | Miscellaneous, Imprimis Pharmaceuticals

Imprimis Signs License Agreement to Bring Proprietary Compounded Ophthalmic Formulations to Ophthalmologists in Canada

Imprimis Pharmaceuticals announced that it has entered into a license agreement with specialty pharmaceutical company, Advanced Dosage Forms, to expand Imprimis' proprietary ophthalmic injectable …

Read the full story

Thursday, August 06, 2015 | Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Expands Distribution of its Proprietary Ophthalmic and Urologic Formulations into Texas and Virginia

Imprimis Pharmaceuticals has expanded the availability of its proprietary ophthalmic and urologic compounded formulations to physicians and patients in Texas, according to a company news release. The …

Read the full story

Wednesday, July 01, 2015 | Miscellaneous, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell

Imprimis Pharmaceuticals announced that the company will ring The Nasdaq stock market closing bell on Thursday, July 2, 2015, according to a company news release. Imprimis is celebrating the growing s…

Read the full story

Tuesday, June 23, 2015 | Cataract Surgery, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Acquires Proprietary Compounded Conscious Sedation Formulations

Imprimis Pharmaceuticals announced that it has acquired the rights to novel proprietary sedation and analgesia/anesthesia formulations that, once prescribed and dispensed for an individual patient, ar…

Read the full story

Wednesday, May 13, 2015 | Earnings & Financials, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Announces $15 Million Term Loan Agreement with Life Sciences Alternative Funding LLC

Imprimis Pharmaceuticals announced it has entered into a loan agreement with IMMY Funding LLC, an affiliate of Life Sciences Alternative Funding LLC (LSAF), a provider of debt capital to fund growth f…

Read the full story
Load More